Detection of myocardial fibrosis in systemic sclerosis by contrast-enhanced magnetic resonance imaging

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 180, Issue 12, 2008, Pages 1054-1060

  Naßenstein, Kai ^a   Breuckmann, F ^a   Huger, M ^b   Ladd, S C ^a   Schlosser, T ^a   Kreuter, A ^b   Barkhausen, J ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CMR; Late gadolinium enhancement; Scleroderma heart disease; Systemic sclerosis

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CONTRAST MEDIA; CROSS-SECTIONAL STUDIES; ENDOMYOCARDIAL FIBROSIS; FEMALE; GADOLINIUM DTPA; HEART SEPTUM; HEART VENTRICLES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PERICARDIAL EFFUSION; SCLERODERMA, SYSTEMIC;

EID: 57649132033     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027864     Document Type: Article

References (40)

1. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81: 139-153
2. Fern C, Di Bello V, Martini A et al. Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. Ann Rheum Dis 1998; 57: 296-302
3. Follansbee WP, Miller TR, Curtiss EI et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990; 17: 656-662
4. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56: 393-394
5. Candell-Riera J, Armadans-Gil L, Simeon CP et al. Comprehensive non-invasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996; 39: 1138-1145
6. Kazzam E, Caidahl K, Hallgren R et al. Mitral regurgitation and diastolic flow profile in systemic sclerosis. Int J Cardiol 1990; 29: 357-363
7. Kazzam E, Waldenstrom A, Landelius J et al. Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis. J Intern Med 1990; 228: 183-192
8. Giunta A, Tirri E, Maione S et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000; 59: 94-98
9. Meune C, Allanore Y, Devaux JY et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004; 31: 1941-1945
10. Kostis JB, Seibold JR, Turkevich D et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988; 84: 1007-1015
11. Steen VD. Systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 641-654
12. Fernandes F, Ramires FJ, Arteaga E et al. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9: 311-317
13. Hunold P, Kreitner KF, Barkhausen J. "Dead or alive?": how and why myocardial viability imaging by cardiac MRI works. Röntgenstr Fortschr 2007; 179: 1016-1024
14. Hunold P, Schlosser T, Vogt FM et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. Am J Roentgenol 2005; 184: 1420-1426
15. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109: 1250-1258
16. Teraoka K, Hirano M, Ookubo H et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004; 22: 155-161
17. Mayes MD. Classification and epidemiology of scleroderma. Semin Cutan Med Surg 1998; 17: 22-26
18. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205
19. Brennan P, Silman A, Black C et al. Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 1992; 31: 457-460
20. Paulus WJ. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998; 19: 990-1003
21. Ladd SC, Wanke I, Gizewski ER et al. First results of a prospective whole-body MR screening study. European Radiology 2007; 17 (supplements): 202
22. Hudsmith LE, Petersen SE, Francis JM et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005; 7: 775-782
23. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444
24. Follansbee WP. Organ Involvement: cardiac. In: Clements PJ, Furst DE (ed). Systemic sclerosis. Baltimore: Wiliams Wilkins, 1996: 333-364
25. D'Angelo WA, Fries JF, Masi AT et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-440
26. Beer M, Buchner S, Wirbelauer J et al. MR imaging and MR spectroscopy for characterization of cardiomyopathies in adolescents - preliminary results. Röntgenstr Fortschr 2007; 179: 932-937
27. Seeger A, Doesch C, Klumpp B et al. MR stress perfusion for the detection of flow-limiting stenoses in symptomatic patients with known coronary artery disease and history of stent implantation. Röntgenstr Fortschr 2007; 179: 1068-1073
28. Schafer R, Wiskirchen J, Guo K et al. Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. Röntgenstr Fortschr 2007; 179: 1009-1015
29. Ishida R, Murata Y, Sawada Y et al. Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000; 21: 729-734
30. Sulli A, Ghio M, Bezante GP et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology 2004; 43: 505-509
31. Chung G, Lahiri A. Myocardial perfusion imaging in modern cardiology. Br J Cardiol 2000; 7: 619-623
32. Beranek JT. Pathogenesis of heart fibrosis in systemic sclerosis. Int J Cardiol 2001; 80: 261-262
33. Conny RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
34. Dumont CA, Monserrat L, Soler R et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2007; 60: 15-23
35. Blyth KG, Groenning BA, Martin TN et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005; 26: 1993-1999
36. Dziadzio M, Giovagnoni A, Pomponio G et al. Acute myocarditis associated with adenoviral infection in a patient with scleroderma. Clin Rheumatol 2003; 22: 487-490
37. Tzelepis GE, Kelekis NL, Plastiras SC et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56: 3827-3836
38. Ferri C, Giuggioli D, Sebastiani M et al. Heart involvement and systemic sclerosis. Lupus 2005; 14: 702-707
39. Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977-1985
40. Allanore Y, Meune C, Vignaux O et al. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 2006; 33: 2464-2469